Priority Research Papers:
LIM kinase inhibitors disrupt mitotic microtubule organization and impair tumor cell proliferation
Metrics: PDF 1098 views | HTML 2067 views | ?
Katerina Mardilovich1, Mark Baugh1, Diane Crighton1, Dominika Kowalczyk1, Mads Gabrielsen1, June Munro1, Daniel R. Croft1, Filipe Lourenco1, Daniel James1, Gabriella Kalna1, Lynn McGarry1, Oliver Rath1, Emma Shanks1, Mathew J. Garnett2, Ultan McDermott2, Joanna Brookfield3, Mark Charles3, Tim Hammonds4 and Michael F. Olson1
1 Cancer Research UK Beatson Institute, Garscube Estate, Glasgow, UK
2 Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, UK
3 Cancer Research Technology Discovery Laboratories, Jonas Webb Building, Babraham Research Campus, Cambridge, UK
4 Cancer Research Technology Discovery Laboratories, London Bioscience Innovation Centre, London, UK
Michael F. Olson, email:
Keywords: cytoskeleton, microtubule, inhibitor, LIMK, kinase
Received: June 23, 2015 Accepted: October 01, 2015 Published: November 03, 2015
The actin and microtubule cytoskeletons are critically important for cancer cell proliferation, and drugs that target microtubules are widely-used cancer therapies. However, their utility is compromised by toxicities due to dose and exposure. To overcome these issues, we characterized how inhibition of the actin and microtubule cytoskeleton regulatory LIM kinases could be used in drug combinations to increase efficacy. A previously-described LIMK inhibitor (LIMKi) induced dose-dependent microtubule alterations that resulted in significant mitotic defects, and increased the cytotoxic potency of microtubule polymerization inhibitors. By combining LIMKi with 366 compounds from the GSK Published Kinase Inhibitor Set, effective combinations were identified with kinase inhibitors including EGFR, p38 and Raf. These findings encouraged a drug discovery effort that led to development of CRT0105446 and CRT0105950, which potently block LIMK1 and LIMK2 activity in vitro, and inhibit cofilin phosphorylation and increase αTubulin acetylation in cells. CRT0105446 and CRT0105950 were screened against 656 cancer cell lines, and rhabdomyosarcoma, neuroblastoma and kidney cancer cells were identified as significantly sensitive to both LIMK inhibitors. These large-scale screens have identified effective LIMK inhibitor drug combinations and sensitive cancer types. In addition, the LIMK inhibitory compounds CRT0105446 and CRT0105950 will enable further development of LIMK-targeted cancer therapy.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.